Search
for
Sort by
Research 30 of 75
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Ritlecitinib: First Approval
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Systemic treatments for alopecia areata: A systematic review
- New drugs under investigation for the treatment of alopecias
- Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Estimation of health utility values for alopecia areata
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- New therapies for alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Clinical Trials and Hair Loss
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Ritlecitinib in severe alopecia areata: a profile of its use
- Common Causes of Hair Loss and Their Treatment Options
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases